$4.2M granted to Seattle Cancer Care Alliance

To date, Swim Across America has contributed close to $4.2 million for clinical research at Seattle Cancer Care Alliance and Fred Hutch. Starting in 2019, funds raised from the SAA-Seattle have gone to support breakthrough research by young investigators. In 2021, six grants were awarded to researchers focused on: lymphoma, sarcoma, breast, pancreatic, and urological cancer research. Below, the grant recipients share progress statements on their research over the last year.

Dr. Meghan Flanagan

Dr. Meghan Flanagan
Research focus: Breast cancer
Project title: Association of HSD3B1 (1245C) genotype with recurrence among post-menopausal women with estrogen receptor- positive, HER2- negative breast cancer
Background: Endocrine (antiestrogen) therapy reduces the risk of recurrence and improves mortality among women with hormone-receptor positive breast cancer. However, approximately one-quarter of women are inherently resistant or develop resistance to endocrine therapy. Ultimately, this research may allow us to identify women with innate endocrine resistance and develop novel therapeutics and treatment strategies.
Progress Statement: The SAA funds were used to evaluate whether an association exists between a mutation in a gene (HSD3B1, involved in hormone biosynthesis) and breast cancer outcomes. Using extensively collected clinical and pathologic data about patient demographics, tumor and treatment data and recurrence rates, we were able to show that women with two mutations in the HSD3B1 gene had higher rates of distant metastatic recurrence compared to those women who did not have this mutation. Future studies will be forthcoming to determine how this mutation may decrease the effectiveness of anti-estrogen medications that are used universally in post-menopausal ER+ breast cancer. This mutation is found in up to 15 percent of ER+ post-menopausal breast cancer patients, and if shown to decrease the effectiveness of anti-estrogen medications, there would be potential indications for alternative treatment strategies in these patients.

Dr. Sita Kugel

Dr. Sita Kugel
Research focus: Pancreatic Cancer
Project title: Exploring novel functions of HMGA2 in pancreatic cancer
Background: Pancreatic Ductal Adenocarcinoma (PDA) is an extremely lethal disease with a 5-year survival rate of less than 10%. Recent work has led to the discovery that PDA can be subdivided into two principal subtypes based on transcriptional signatures: classical and quasi-mesenchymal (QM). The QM PDA subtype is more aggressive and has the worst overall survival. Our laboratory has been focused on understanding of the mechanisms that drive each subtype in hopes of identifying therapeutic vulnerabilities that may be exploited in the clinic.
Progress Statement: Within an already challenging malignancy, there are transcriptional subtypes of pancreatic ductal adenocarcinoma that are especially lethal. Understanding what defines each subtype, as well as their susceptibilities and mechanisms of resistance, will help to identify new targeted therapies or combination therapies and lead to more treatment options for this devastating disease.

Dr. Jonathan Sham

Dr. Jonathan Sham
Research focus: Pancreatic Cancer
Project title: Novel Drug- eluting Biopolymer to Reduce Pancreatic Fistula and Improve Outcomes After Pancreatic Surgery
Background: Pancreatectomy is the mainstay of any potentially curative treatment regimen for pancreatic cancer. Despite an overall improvement in the safety of pancreatic surgery over the past several decades, the morbidity of pancreatectomy remains exceedingly high. The most significant complication after pancreatic surgery is postoperative pancreatic fistula (POPF), which occurs in up to 60% of cases. The use of a biopolymer, poly(Nisopropylacrylamide) (PNIPAM), is an innovative method to prevent leakage of pancreatic juice from the cut surface of the gland, while the suspended octreotide- eluting microspheres will simultaneously reduce baseline pancreatic fluid secretion. This novel dual-action approach will be tested in a validated rat model of POPF with the goal of rapid clinical translation and patient benefit.
Progress Statement: Swim Across America is advancing our work to improve outcomes after pancreatic surgery. Their support is enabling a trailblazing collaboration between surgeons and bioengineers to develop novel ways to stop leaks after pancreas surgery and make patients live happier, healthier and longer lives. Polymer synthesis is moving forward, and two teams are working on creating and testing polymers with different characteristics for use in our animal experiments.

Dr. Jordan Gauthier

Dr. Jordan Gauthier
Research focus: CAR T-cell therapy
Project title: Factors associated with failure of CD19 CAR T cells in diffuse large B cell lymphoma
Background: We are investigating two factors potentially critical to failure of CD19 CAR T-cell therapy for DLBCL: a) T cell dysfunction, impeding the generation of functional CAR T cells during manufacturing; b) the suppressive tumor microenvironment (TME). Our studies will better characterize T cell dysfunction and the TME as core mechanisms of failure of CD19 CAR T cells and identify potential targets to improve outcomes of CAR T-cell therapy for DLBCL.
Progress Statement: The Swim Across America grant allowed us to explore the two following aims.
Aim 1: To determine whether exhausted T cells are associated with treatment failure after CAR T-cell therapy for diffuse large B-cell lymphoma (DLBCL). We analyzed blood samples from 34 DLBCL patients treated on a clinical trial of CAR T-cell therapy. While we did not confirm an association between exhausted T cells and treatment failure, we found that a higher proportion of terminally differentiated T cells may have an adverse impact on the outcomes of CAR T-cell therapy.
Aim 2: To determine if an exhausted gene signature in T cells from lymphoma tumors is associated with treatment failure, we analyzed pre-treatment tumor biopsies obtained from 17 patients receiving CAR T-cell therapy. In biopsies from patients in complete response after CAR T-cell therapy, we found that T cell-associated genes were overexpressed compared to patients not in complete response after treatment. This suggests that tumors more permissive to T cell infiltration might respond better to CAR T-cell therapy. So far, we have not confirmed that an exhausted gene signature is associated with treatment failure. The SAA grant has been used to design and optimize novel assays that will allow us to further address this aim in the future.

Dr. John Lee

Dr. John Lee
Research focus: Sarcoma
Project title: Development of STEAP1 chimeric antigen receptor T-cell therapy for Ewing sarcoma
Background: Ewing sarcoma (ES) is a soft tissue/bone cancer with 200 newly diagnosed adolescents/young adults per year in the United States. Patients with metastatic dissemination face a very grim prognosis as available treatments are unable to eradicate the disease. New therapeutic approaches are needed. If successful, these studies will help lay the groundwork for the development and clinical translation of a first-in-field STEAP1 CAR T-cell immunotherapy for ES.
Progress Statement: We applied the Swim Across America grant to evaluate whether a novel chimeric antigen receptor (CAR) T cell therapy targeting the protein STEAP1 could be an effective strategy to treat Ewing sarcoma. Our results indicate that human Ewing sarcoma tumor models commonly express STEAP1 and are susceptible to killing by STEAP1 CAR T cells. In related studies, we have also determined that STEAP1 CAR T cell therapy appears safe in a novel mouse model that we engineered to express human STEAP1. Together, these findings provide the rational to translate STEAP1 CAR T cell therapy into clinical trials for Ewing sarcoma in the near future.

Dr. Adam Gadzinski

Dr. Adam Gadzinski
Research focus:
Urological cancer
Project title: Interstate Telehealth to improve access to urological cancer care among rural patients.
Background: Timely access to urological cancer care is challenging for rural patients who often travel great distances to tertiary centers. This is particularly true for patients residing in the WWAMI (Washington, Wyoming, Alaska, Montana, Idaho) region. We hypothesize that Telehealth will provide similar patient satisfaction, reduced costs, and earlier time to treatment. We further hypothesize that implementation of the interstate Telehealth program will decrease referral to visit time and increase clinical efficiency. Lastly, we hypothesize that providing Telehealth appointments will increase the frequency of referrals from rural areas. We anticipate that implementation of our interstate Telehealth program will improve access to urological cancer care for rural and underserved patients throughout the WWAMI region.
Progress Statement: Our SAA grant has been used to support our telemedicine research efforts to assess the quality of telemedicine visits for cancer patients from rural areas and the Pacific Northwest states. We have demonstrated that telemedicine visits save cancer patients and their families a significant amount of time and money that would have been spent traveling to doctor appointments. We also found that patients are very satisfied with receiving cancer care remotely via telemedicine, especially during the COVID-19 pandemic.

More than $2M Awarded to Chicago Rush University Medical Center by Swim Across America

With the support of Swim Across America grant funding, researchers at Rush University Medical Center are gaining momentum in their quest to discover the early detection tools and treatment options of the future in the fight against cancer. RUSH’s experts intimately understand the physical, emotional and financial burdens of cancer on patients’ lives, and they refuse to let the disease rest as the second leading cause of death in the U.S. Since 2012, Swim Across America–Chicago has awarded More than $2M that has funded these early stage research projects.

Dr. Carl Maki

Grant Recipient: Carl Maki, PhD
Professor in the Department of Anatomy & Cell Biology at Rush Medical College

Project: Targeting proteins to improve drug responses for patients with treatment-resistant breast and lung cancers

Project Details: By studying cancer at the molecular level, Maki and his team have made significant strides in identifying promising new options for treatment-resistant breast and lung cancers.

In 2015 Maki received an SAA grant to study a family of enzymes known as prolyl peptidases (which regulate blood pressure and appetite) as a possible mechanism to help prevent or alleviate resistance to the drug tamoxifen, one of the most widely used therapies for the 80% of women with breast cancer whose tumors are considered estrogen receptor-positive. Maki and his team found that an enzyme inhibitor for prolyl peptidases, used in conjunction with tamoxifen, effectively killed breast cancer cells in rodents. Using these promising findings, Maki applied for and received a prestigious R01 research award for continued study from the National Institutes of Health and a grant from the Department of Defense to extend this research into triple-negative breast cancer.

In 2020 Maki was awarded another SAA grant to study proteins called histone demethylases in non-small cell lung cancer. Among the deadliest of all cancers, this accounts for about 4 in 5 lung cancer cases. Maki and his colleagues are studying how these proteins may allow lung cancer cells to resist the drugs currently used to treat the disease. By blocking these proteins, the team has been able to kill lung cancer cells in laboratory studies and lung tumors in mice. They identified a novel mechanism for how these inhibitors improve treatment outcomes and recently published their results.

“What starts out as an idea might result in something great,” Maki said. “SAA gives less established researchers a chance and helps all researchers fund pilot projects that ultimately can lead to bigger things.”

Dr. Animesh Barua

Grant Recipient: Animesh Barua, PhD
Associate Professor in the Department of Anatomy & Cell Biology at Rush Medical College
Director of the Proteomics Core and MicroRNA and Gene Expression Core

Project: Seeking an improved early detection test for ovarian cancer

Project Details: Throughout his career, Barua has relentlessly pursued the development of an effective early detection test for ovarian cancer. With an SAA grant received in 2020, he and his team are drawing upon extensive experience with immunoassays and ultrasound imaging of ovarian tumors to take the next steps forward in this important area of research. In this study, Barua’s lab is developing a fresh approach to early detection testing involving the fimbriae (fingerlike protein branches that guide an egg during ovulation) of the fallopian tubes. Emerging information shows that high-grade serous carcinoma — the most malignant and most common type of ovarian cancer — originates from the fimbriae. The aims of Barua’s study include identifying specific protein markers associated with cancer development in the fimbriae and determining the efficacy of these markers in predicting cancer growth.

Dr. Amanda Marzo

Grant Recipient: Amanda Marzo, PhD
Assistant Professor in the Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy at Rush Medical College

Project: Bolstering the body’s natural immune response for greater success in the battle against breast cancer

Project Details: Tumor-infiltrating CD8 T-cells are essential for tumor immunity. However, many of these cells become exhausted and are unable to protect against tumor growth. Key molecules known as checkpoint inhibitors, such as programmed death-ligand 1 (PD-L1) expressed on tumor cells and programmed cell death protein 1 (PD-1) expressed on CD8 T-cells, have been shown to be a hallmark of CD8 T-cell exhaustion. For most tumors, blocking PD-1/PD-L1 signaling does not result in tumor rejection. A main cause for the ineffectiveness of checkpoint blockade immunotherapy lies in the dysfunctional state of CD8 T-cells once they enter the tumor. CD8 T-cells are specialized in killing tumor cells but face multiple suppressive signals that dampen their ability to effectively respond. Using an SAA grant received in 2019,Marzo and her colleagues seek to improve scientists’ understanding of how other immune-modulating treatments can improve CD8 T-cell responsiveness to checkpoint inhibitors. Specifically, the researchers aim to determine if metformin, an anti-diabetic drug, could enhance tumor-infiltrating CD8 T-cell responsiveness to PD-1 blockade therapy by altering breast cancer metabolism. The team also seeks to establish if bolstering the number of infiltrating CD8 T-cells into the tumor using interleukin-15 complexes (known to cause proliferation of cells and increase their killing ability) in combination with PD-1 blockade therapy could induce regression of established breast tumors and lead to long-term tumor immunity. Marzo and her team plan to publish the results of their study and are using preliminary data generated from this research to apply for a federal R21 grant.

Dr. Alan Blank

Grant Recipients: Alan T. Blank, MD, MS
Assistant Professor in the Department of Orthopedic Surgery, Section of Orthopedic Oncology at Rush Medical College

Jitesh Pratap, PhD
Associate Professor in the Department of Anatomy & Cell Biology at Rush Medical College

Dr. Jitesh Pratap

Project: Pursuing therapeutic approaches to prevent breast cancers from

metastasizing to the bones

Project Details: In this study funded by a 2019 SAA grant, Blank and Pratap seek to fulfill a need for the development of a therapy that can prevent primary breast cancers from metastasizing to the bones and surviving there. The researchers hypothesize, based on results of previous studies, that a subgroup of patients with breast cancer that has metastasized to the bone has high levels of autophagy (a process of recycling of cellular components), Runx2 proteins and acetylated α-tubulin — worsening their chances of survival. To investigate this, the researchers are working to determine the clinicopathologic association with the autophagy pathway in tumor samples from patients with cancer that has metastasized to the bone. They are also creating patient-derived xenograft models of bone metastasis. Blank and Pratap hope the results of this study will propel the development of better combinatorial therapeutic approaches to treat bone metastasis.

Dr. Faraz Bishehsari

Grant Recipient: Faraz Bishehsari, MD, PhD
Associate Professor of Medicine & the Graduate College in the Department of Internal Medicine, Division of Digestive Diseases and Nutrition, Section of Gastroenterology at Rush Medical College
Associate Director for Molecular & Translational Research for the Rush Center for Integrated Microbiome & Chronobiology Research

Project: Pursuing precision medicine to improve outcomes for pancreatic cancer patients

Project Details: Patients with pancreatic ductal adenocarcinoma — the most common form of pancreatic cancer — face poor survival rates, with only 6%-8% of patients surviving five years after diagnosis. This cancer does not respond well to targeted therapies. Bishehsari and his colleagues received an SAA grant in 2019 to establish a platform towards precision medicine in order to tailor therapies based on patients’ individual tumor characteristics. The researchers have developed primary cancer cells from a small tissue sample obtained during diagnostic pancreatic biopsies from pancreatic ductal adenocarcinomas. Molecular profiling of these patient-derived tumor organoids explained the variation in response to a variety of conventional and investigational therapies. They are optimizing this platform to help eventually establish individualized treatments for pancreatic cancer patients.

Dr. Jeff Borgia

Grant Recipient: Jeffrey A. Borgia, PhD
Associate Professor in the Department of Anatomy & Cell Biology at Rush Medical College
Director of the Rush University Cancer Center Biorepository and Rush Biomarker Development Core

Project: Identifying biomarkers for the improved evaluation and treatment of stage I non-small cell lung cancer

Project Details: Lung cancer is the leading cause of cancer-related mortality in the United States, but evidence is surfacing that widespread lung cancer screening programs may improve patient outcomes when the disease is detected early. Borgia and his team received an SAA grant in 2020 to develop a new diagnostic method to improve physicians’ ability to predict the recurrence of stage I non-small cell lung cancer, or NSCLC. This would help physicians identify patients who would benefit from adjuvant treatment options or closer surveillance. The aims of this study include identifying biomarkers for disease recurrence in stage I NSCLC patients and evaluating these biomarkers for their value in predicting recurrence.

Swim Across America has supported cancer research at Rush University Medical Center since 2012 through more than $2 million in grant funding. Together, Swim Across America and RUSH are relentlessly fighting cancer, working to save lives.

Colorado Community Makes Waves to Benefit Children’s Hospital Colorado

Picture a sunny and warm mid-August morning in Colorado. Retired Olympians such as Missy Franklin and George DiCarlo are smiling with water enthusiasts of all ages and abilities. They enter the water of Chatfield Reservoir in Littleton to “Make Waves to Fight Cancer” with the Swim Across America-Denver charity swim. There’s a sense of community as supporters and family cheer for them. Not because they’ll be racing for first place, rather because they’re all there to raise money that will provide grants for pediatric cancer at Children’s Hospital Colorado.

Created in 2018, Swim Across America-Denver has granted $545,917 to research projects at the Center for Cancer and Blood Disorders at Children’s Colorado. Uniquely, all the proceeds from Swim Across America-Denver stay in our community to fund research projects at Children’s Colorado where philanthropic grants from Swim Across America are necessary to make progress in giving hope to kids and their families who are fighting cancer. Here are the projects that are being funded by SAA:

  • The acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) research project, led by Drs. Amanda Winters, Taizo Nakano, and Craig Forester, aimed at bringing new therapies into phase II of clinical trials for pediatric MDS and AML to better define how to diagnose, classify and treat MDS patients.
  • The tumor research project, led by Dr. Adam Green, which will characterize the immune response to new brain tumors to better establish which types are amenable to cancer immunotherapy and provide a new prognostic marker for these diseases.
  • The sepsis biomarker project, led by Dr. Leonora Slatnick, will lead to novel ways of diagnosing and managing infectious complications in immunosuppressed patients.
  • The CAR-T Cell project, led by Dr. Lindsey Murphy and collaborating with Dr. Winters and members of the BMT-Cellular Therapeutics team, aims to use novel laboratory methods for detecting CAR-T cells in patients receiving those therapies to better understand how patients respond to these therapies and improve cure rates.

“With [Swim Across America grants] we’re building the largest national database on pediatric myelodysplastic syndrome (MDS) to collect data on all of the past and future children with this life-threatening disorder. SAA’s contribution will help encourage research collaboration at over 50 children’s hospitals to enter data that will help develop a national standards-of-practice to treat pediatric MDS,” said Taizo Nakano, MD.

Grants from SAA will also be used to fund site initiation of a nationwide clinical trial for pediatric MDS at Children’s Colorado and will also be critical for Dr. Forester and Dr. Winters as they investigate the biological activity of the drug combination being tested.

“This will allow us to understand why the drugs work for pediatric MDS and perhaps enable us to predict at diagnosis which children with MDS are more or less likely to benefit from these drugs,” said Amanda Winters, MD.

“We welcome and invite our Colorado community to join us,” said Nicole Vanderpoel and Jessica Vitcenda, community leaders for SAA—Denver. “You can swim, volunteer or do a virtual activity with all the proceeds staying in Denver to benefit Children’s Colorado.”

Learn more about SAA-Denver and how you can get involved by visiting Swim Across America – Denver.  

Swim Across America – Charleston-Kiawah Researcher Awarded 5-Year NCI Grant

Swim Across America is proud to share that MUSC Hollings Cancer Center researcher Haizhen (Jen) Wang, Ph.D., has been awarded a five-year $344,000 per year grant by the National Cancer Institute (NCI) to pursue her early investigator studies in leukemia. Prior to receiving NCI funding, Dr. Wang’s research was supported by $65,000 in grants from the Swim Across America – Charleston-Kiawah charity swim held annually at Kiawah Island Golf Resort.

Swim Across America helps fill the funding void by providing grants so doctors can conduct clinical trials and research that can lead to breakthroughs in detection and treatment. When this funding leads to larger grants like Dr. Wang’s with the NCI, it’s a win not only for future patients but for all Swim Across America participants, donors and beneficiary partners.

According to the Hollings website, Dr. Wang’s research “focuses on uncovering the connection between cancer metabolism and cancer immunology. Her research has shown that a molecule called cyclin-dependent kinase 6 (CDK6) may be a key regulatory molecule in cancers such as leukemia.” The grant funding has already started this year and allows Dr. Wang to add research team members. The grant also has the unique option to extend two more years.

SAA-Charleston-Kiawah has supported MUSC Hollings Cancer Center since 2019 and has welcomed Dr. Wang, her family and other members of the Hollings team to participate in our annual charity swim.

To learn more about the impact or donate, please visit swimacrossamerica.org/kiawah

SAA – San Francisco’s Susan Helmrich Interviews “Why We Swim” Author Bonnie Tsui in Virtual Conversation

 

Swim Across America – San Francisco Event Director and cancer survivor Susan Helmrich will be interviewing “Why We Swim” author Bonnie Tsui in a Zoom Conversation this Wednesday, June 3rd. Topics will include all things swimming, community and the reasons “why we swim.” Susan Helmrich has been the Event Director for SAA – San Francisco for 13 years and her “Team Susan Survives” is consistently a top national fundraising team for Swim Across America.

Susan has been a member of U.S. Masters Swimmers for decades and a daily swimmer for most of her life — except during her three bouts with cancer. An epidemiologist, she has studied how over-the-counter and prescription medications affect women’s health and the effects of physical activity on health and well-being” says Berkeley City Club, the host of the virtual conversation.

Both women are avid swimmers and excited to talk about what draws them to the water and what they love about swimming. The Zoom Conversation will take place on Wednesday, June 3rd at 7:00 p.m. PST (10:00 p.m. EST). Swimmers and non-swimmers alike are invited to participate. RSVP here: sydneyc@swimacrossamerica.org.

 

 

Swim Across America Thanks Healthcare Workers at Local Beneficiaries

Swim Across America is finding ways to continuing supporting local beneficiaries during this challenging time. Local leadership has been donating meals to selfless healthcare workers at our beneficiary institutions as they continue putting themselves at risk to serve and protect all of us during this crisis. Our unwavering commitment to support our beneficiaries remains, and now more than ever we stand by each of them.

SAA – Houston

MD Anderson Cancer Center

93577600_1415749531941024_1891633266516033536_n

Swim Across America – Houston treated the Pediatric and Brain & Spine Teams at MD Anderson Cancer Center to lunch as a way to express their sincerest appreciation for their service.

SAA – Dallas

Innovative Clinical Trials Center – Baylor Scott & White Health

92758907_2582859791955652_2566917183326126080_n

A big thumbs up from Dr. Becerra after the Swim Across America – Dallas team brought “Taco Tuesday” to the staff of the Swim Across America Innovative Clinical Trials Center at Baylor Scott & White Health.

SAA – San Francisco Bay

UCSF Benioff Children’s Hospitals

98089073_10157550372318737_178459000705122304_n

SAA – San Francisco Bay provided their beneficiary and partners UCSF Benioff Children’s Hospitals with a nutritious breakfast last week to thank them for their continued efforts in supporting the Survivors of Childhood Cancer Program. Thanks to our friends Checkers Catering & Special Events for providing the scrumptious breakfast to these Capeless Heroes!!

SAA – Atlanta

Children’s Healthcare of Atlanta

Swim Across America – Atlanta had Chick-Fil-A cookies dropped off for the past and present medical staff who have been funded by Swim Across America to show our appreciation for all of their hard work. They returned the love with some fun photos with their cookies.

SAA – Long Island Sound

NY Presbyterian Hospital &

Memorial Sloan Kettering Cancer Center

Swim Across America – Long Island Sound has been busy reaching out to their beneficiaries and scheduling these meal drop-offs. The SAA – LIS team brought breakfast to the nurses at the front line in the Urgent Care Unit at Memorial Sloan Kettering. They also provided lunch to the ICU team at NY Presbyterian Hospital.

A huge thank you to all healthcare workers for your courage and unselfish commitment to patients and the communities you serve!

How Does the CARES Act Affect My 2020 Donation?

CARES Act for Nonprofits – On Friday, March 27, Congress passed and the President signed into law the Coronavirus Aid, Relief, and Economic Security (CARES) Act, a $2 trillion economic stimulus package legislated to provide immediate relief for nonprofits. You can help give families affected by cancer hope when you make a donation to Swim Across America.

Details About CARES Act

The inclusion of an expanded charitable giving incentive is a critical acknowledgement by Congress that the work of nonprofits like Swim Across America are essential services. Indeed, cancer isn’t taking a break and our mission continues to be critical as we raise funds and provide grants to our world-class beneficiaries. It is the first time Congress has passed this type of giving incentive in response to disaster or national emergency. 

Here Are The Highlights

IMPORTANT: New Deduction Available: Up to $300 per tax filing in annual charitable contributions. It is an “above the line” adjustment to income that will reduce a donor’s adjusted gross income (AGI), and thereby reduce taxable income. This is particularly beneficial to people who take the standard deduction when filing their taxes (in other words for taxpayers who do not itemize their deductions). A donation to a donor advised fund (DAF) does not qualify for this new deduction. 

New Charitable Deduction Limits: As part of the bill, individuals and corporations that itemize can deduct much greater amounts of their contributions. Individuals can elect to deduct donations up to 100% of their 2020 AGI (up from 60% previously). Corporations may deduct up to 25% of taxable income, up from the previous limit of 10%. The new deduction is for gifts that go to a public charity, such as Swim Across America. The old deduction rules apply to gifts to private foundations. The higher deduction does not apply to donations directly to a DAF. 

If your assets are substantial enough that you can give more than your income this year, you won’t lose the deduction for the excess amount. You can use it next year, as has always been the case.

Required Min. Distributions Waived in 2020 for Most Donors: RMD for individuals over age 70 ½ are suspended until 2021. This includes distributions from defined benefit pension plans and 457 plans. The RMD is an attractive way for donors to make a significant charitable gift directly from their IRA to a charity through a qualified charitable contribution (QCD) while avoiding taxable income. The suspension of the RMD may dampen somewhat the incentive for a donor who makes a gift from their IRA to count toward that minimum. However, the tax benefit of the QCD remains. 

The takeaway – donors directing a QCD to charity this year (up to $100,000 per individual) will still reduce their taxable IRA balance. This allows all taxpayers, itemizers and non-itemizers alike, to direct gifts from their IRA to charities in a tax efficient manner. 

DONATE TO SWIM ACROSS AMERICA TODAY

If you have questions or would like assistance making a donation, you can contact us at info@swimacrossamerica.org

This information is not intended as legal or tax advice. For such advice, please consult an attorney or tax advisor. Figures cited in any examples are for illustrative purposes only. References to tax rates include federal taxes only and are subject to change. State law may further impact your individual results.

14290073724_611e4cb113_k

Speedo USA and Swim Across America Donating Goggles

Speedo USA and Swim Across America have teamed up to donate 2,000 goggles to Swim Across America hospital beneficiaries. The goggles are offered as protective eyewear to hospital medical staff.Screen Shot 2020-04-06 at 1.03.35 PM

“Our hospital partners shared a need for protective eyewear so we reached out to Speedo USA to see if they might be able to help,” commented Rob Butcher, Swim Across America CEO.

IMG_8416
Swim Across America-Dallas team captain Alan Wright of Baylor Oncology shows off his SAA spirit.

“Many of Speedo’s athletes support Swim Across America so when we were approached with the need and that we could help, we were delighted to do so,” shared Andy Long, CEO of Pentland Brands.

Swim Across America hosts charity swims with the proceeds funding cancer research. If you feel inspired, you may donate to Swim Across America through this link.

Swim Across America Awards a Record $6 Million in Grants to Fight Cancer for 2020

48138357962_e6a8679aa6_k (1)

In 1987, an inaugural charity swim was hosted across Long Island Sound that raised $5,000 for cancer research. Since then, Swim Across America charity swims have granted nearly $100M that has funded innovative cancer research and clinical trials. Swim Across America grants have played a major role in the development of immunotherapy, detection, gene therapy and personalized medicine. The impact is that families who hear “you have cancer” are more than ever hearing “there is hope.”

In 2020, Swim Across America will be awarding a record $6 million in cancer research grants that will fund more than 50 projects and programs at the following beneficiaries: Alliance for Cancer Gene Therapy (Connecticut), Baylor Scott & White Sammons Cancer Center (Dallas), Cancer Support Team (Westchester, NY), RUSH University Medical Center (Chicago), Children’s Healthcare of Atlanta, Cold Spring Harbor Laboratory (New York), Columbia University Medical Center (New York), Dana- Farber Cancer Institute (Boston), Feinstein Institute for Medical Research (New York), Medical University of South Carolina Hollings Cancer Center (Charleston), Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (Baltimore), Johns Hopkins All Children’s Hospital (Tampa), Atrium Health Levine Cancer Institute (Charlotte), MassGeneral Hospital for Children (Boston), MD Anderson Cancer Center (Houston), Memorial Sloan Kettering Cancer Center (New York), Moffitt Cancer Center (Tampa), Nantucket Cottage Hospital, Palliative and Support Care of Nantucket, Siteman Cancer Center (St. Louis), Seattle Cancer Care Alliance, UC Benioff Children’s Hospitals (San Francisco and Oakland), Children’s Hospital Colorado (Denver), University of Michigan Rogel Cancer Center (Detroit), VCU Massey Cancer Center (Richmond) and Women and Infants Hospital (Rhode Island).

In addition to these grants that are being funded by Swim Across America charity swims within their community, Swim Across America is awarding $120,000 in grants to the Conquer Cancer Foundation (American Society of Clinical Oncology—ASCO) and the American Association for Cancer Research (AACR) that will fund young investigators who have promising ideas to fight cancer.

For more information, please visit swimacrossamerica.org

Swim Across America Partners with United Airlines for “Miles on a Mission” Program

Swim Across America and United Airlines are partnering for United’s “Miles on A Mission” program where United MileagePlus members can give back to charities by donating their airline miles. Check out their promotional video for the program here.

When donating to SAA, your miles will be used to cover travel for special guests attending Swim Across America charity swims. The miles will be used to offset travel costs we would have otherwise paid for, meaning more money can be granted to beneficiary hospitals.

The campaign will run until November 22 or until we reach our goal set at 250,000 miles. Help us reach our goal and take our impact further. Please share with friends and family for the biggest impact.

Ready to donate miles? Click here: bit.ly/SAAMilesonaMission

0